<SEC-DOCUMENT>0001062993-15-005296.txt : 20151006
<SEC-HEADER>0001062993-15-005296.hdr.sgml : 20151006
<ACCEPTANCE-DATETIME>20151006160219
ACCESSION NUMBER:		0001062993-15-005296
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20151001
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151006
DATE AS OF CHANGE:		20151006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51652
		FILM NUMBER:		151146166

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences  Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR></B>Washington, D.C.
20549<B> </B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center>Current Report<BR>Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934</P>
<P align=center>Date of Report (Date of earliest event reported): <B><U>October
1, 2015 </U></B></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES CORP.</FONT></U></B><B>
<BR></B>(Exact name of registrant as specified in its charter)</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-51652 </U></B></TD>
    <TD align=center width="33%"><B><U>20-8365999 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction </TD>
    <TD align=center width="33%">(Commission </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>of incorporation) </TD>
    <TD align=center width="33%">File Number) </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE>
<P align=center><B><U>51 West 52nd Street, 7th Floor, New York, NY USA 10019
<BR></U></B>(Address of principal executive offices) (Zip Code)</P>
<P align=center>Registrant's telephone number, including area code
<B><U>1-844-689-3939 </U></B></P>
<P align=center><B><U>Not Applicable <BR></U></B>(Former name or former address,
if changed since last report.) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below): </P>
<P align=justify>[&nbsp; ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</P>
<P align=justify>[&nbsp; ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)</P>
<P align=justify>[ &nbsp;] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</P>
<P align=justify>[&nbsp; ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify><B>Item 3.03. Material Modification to Rights of Security
Holders. </B></P>
<P align=justify>On October 2, 2015, the Board of Directors (the &#147;<U>Board</U>&#148;)
of Anavex Life Sciences Corp., a Nevada corporation (the &#147;<U>Company</U>&#148;),
approved a reverse stock split of the Company&#146;s common stock, par value $0.001
per share (&#147;<U>Common Stock</U>&#148;), at a ratio of 1 for 4 (the &#147;<U>Reverse
Split</U>&#148;). The Company anticipates that the Reverse Split will be effective as
of 4:30 p.m. Eastern Time on October 6, 2015 (the &#147;<U>Split Effective
Date</U>&#148;), contingent upon approval from the Financial Industry Regulatory
Authority (&#147;<U>FINRA</U>&#148;). </P>
<P align=justify>On October 6, 2015, the Company filed a Certificate of Change (the &ldquo;<u>Certificate</u>&rdquo;) to effect the Reverse Split pursuant to Nevada Revised Statutes Sections 78.207 and 78.209 with the Secretary of State of the State of Nevada. Under Nevada law, the Company&rsquo;s Articles of Incorporation will be deemed amended at the effective time on the Split Effective Date as provided in the Certificate. The Certificate is not effective until the Split Effective Date. In addition, because the Reverse Split was approved by the Board  in accordance with NRS Section 78.207, no stockholder approval is required.</P>
<P align=justify>The Reverse Split will not be effected until the Company
receives approval from FINRA. On the Split Effective Date, every four shares of
the Company&#146;s issued and outstanding Common Stock will be automatically
converted into one newly issued and outstanding share of Common Stock, without
any change in the par value per share. Any fractional shares resulting from the
Reverse Split will be rounded up to the nearest whole share. The Reverse Split
will reduce the number of shares of the Company&#146;s Common Stock outstanding from
400,000,000 to approximately 100,000,000. Immediately after the Reverse Split,
each stockholder&#146;s percentage ownership interest in the Company and proportional
voting power will remain unchanged except for minor adjustments that will result
from rounding fractional shares into whole shares. The rights and privileges of
the holders of shares of Common Stock will be substantially unaffected by the
Reverse Split. All options, warrants and convertible securities of the Company
outstanding immediately prior to the Reverse Split will be appropriately
adjusted accordingly. </P>
<P align=justify>Once effective, the Company&#146;s Common Stock will trade under the
symbol &#147;AVXLD&#148; for a period of 20 business days, after which the &#147;D&#148; will be
removed from the trading symbol, which will revert to the original symbol of
&#147;AVXL&#148;. In connection with the Reverse Split, the CUSIP number for the Company&#146;s
Common Stock will also change. </P>
<P align=justify>Stockholders who are holding their shares in electronic form at
brokerage firms do not have to take any action as the effect of the Reverse
Split will automatically be reflected in their brokerage accounts. </P>
<P align=justify>Stockholders holding paper certificates may (but are not
required to) send the certificates to the Company&#146;s transfer agent at the
following address: </P>
<P style="MARGIN-LEFT: 5%" align=justify>Nevada Agency and Transfer Company
<BR>50 West Liberty Street, Suite 880 <BR>Reno, NV 89501</P>
<P align=justify>The transfer agent will issue a new share certificate
reflecting the terms of the Reverse Split to each requesting stockholder. </P>
<P align=justify>The Company issued a press release announcing the Reverse Split
on October 6, 2015, a copy of which is furnished herewith as <U>Exhibit
99.1</U>. </P>
<P align=justify><U>Exhibit 99.1</U>, is being furnished and shall not be deemed
&#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section. </P>

<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A><P align=justify><B>Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.</B> </P>
<P align=justify>Effective October 1, 2015 (the &#147;<U>Effective Date</U>&#148; ), the
Board appointed Sandra Boenisch, to serve as the Company&#146;s Principal Financial
Officer until the earlier of a successor&#146;s appointment or her resignation. </P>
<P align=justify>Ms. Boenisch is a Chartered Professional Accountant (CPA, CGA)
with 14 years of accounting, audit, and financial reporting experience in a
variety of industries, both in the United States and Canada. Ms. Boenisch has
been an independent consultant, providing financial reporting services to a
range of public companies in the United States and Canada since January 2012.
From 2008 until 2012, Ms. Boenisch was employed at BDO Canada LLP (Vancouver,
BC) where she was hired as a Senior Accountant and was later promoted to
Manager, Audit Assurance. Ms. Boenisch specialized in managing assurance
engagements for public companies in the United States and Canada. Prior to that,
Ms. Boenisch worked for a public accounting firm beginning in 2001. As an
independent consultant, Ms. Boenisch has acquired considerable experience in
finance, governance, and regulatory compliance.</P>
<P align=justify>Ms. Boenisch, age 34, has no family relationship with any other
officer or director of the Company. With respect to the Company, Ms. Boenisch
has not had a direct or indirect material interest in any transaction described
in Item 404(a) of Regulation S-K. In connection with Ms. Boenisch&#146;s appointment
as Principal Financial Officer, the Company and Ms. Boenisch entered into an
employment agreement commencing on October 1, 2015 and ending on September 30,
2017, whereby: (a) the Company shall pay to Ms. Boenisch an annual base salary
of Seventy-Eight Thousand and 00/100 Canadian Dollars ($78,000 CAD), with Ms.
Boenisch being eligible for bonuses and salary increases; (b) Ms. Boenisch shall
receive a sign-on stock option grant; and (c) Ms. Boenisch shall be able to
participate in the Company&#146;s employee benefit plans.</P>
<P align=justify><B>Item 5.03. Amendment to Articles of Incorporation or Bylaws;
Change in Fiscal Year.</B></P>
<P align=justify>The information set forth in Item 3.03 of this Current Report
on Form 8-K is incorporated by reference into this Item 5.03. A copy of the
Certificate is filed as <U>Exhibit 3.1</U> to this Current Report on Form 8-K.
</P>
<P align=justify><B>Item 9.01.</B> <B>Financial Statements and Exhibits.
</B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%" >
      <P align=justify>&nbsp;</P></TD>
    <TD vAlign=top width="5%">
      <P align=justify>(a) </P></TD>
    <TD>
      <P align=justify>Not applicable</P></TD></TR>
  <TR>
    <TD width="5%">
      <P align=justify>&nbsp;</P></TD>
    <TD vAlign=top width="5%">
      <P align=justify>(b) </P></TD>
    <TD>
      <P align=justify>Not applicable</P></TD></TR>
  <TR>
    <TD width="5%">
      <P align=justify>&nbsp;</P></TD>
    <TD vAlign=top width="5%">
      <P align=justify>(c) </P></TD>
    <TD>
      <P align=justify>Not applicable</P></TD></TR>
  <TR>
    <TD width="5%">
      <P align=justify>&nbsp;</P></TD>
    <TD vAlign=top width="5%">
      <P align=justify>(d) </P></TD>
    <TD>
      <P align=justify><U>Exhibits</U>.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="10%"
      align=left vAlign=top noWrap style="BORDER-BOTTOM: #000000 2px solid">&nbsp;<B>EXHIBIT NO.</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 2px solid" vAlign=top noWrap align=center
    width="73%" ><B>DESCRIPTION</B> </TD>
  <TD style="BORDER-BOTTOM: #000000 2px solid" vAlign=top noWrap align=center
    width="17%"><B>LOCATION</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD vAlign=top align=left bgColor=#eeeeee><a href="exhibit3-1.htm">Exhibit 3.1
    </a> </TD>
    <TD vAlign=top align=left width="73%" bgColor=#eeeeee
      ><a href="exhibit3-1.htm">Certificate of Change </a> </TD>
    <TD vAlign=top align=center width="17%" bgColor=#eeeeee>
    <a href="exhibit3-1.htm">Provided
    herewith </a> </TD>
  </TR>
  <TR>
    <TD vAlign=top align=left>&nbsp;</TD>
    <TD vAlign=top align=left width="73%" >&nbsp;</TD>
  <TD vAlign=top align=center width="17%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD vAlign=top align=left bgColor=#eeeeee><a href="exhibit99-1.htm">Exhibit 99.1
    </a> </TD>
    <TD vAlign=top align=left width="73%" bgColor=#eeeeee >
    <a href="exhibit99-1.htm">Press
      Release dated October 6, 2015 regarding Reverse Stock Split </a> </TD>
    <TD vAlign=top align=center width="17%" bgColor=#eeeeee>
    <a href="exhibit99-1.htm">Provided
    herewith </a> </TD>
  </TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A>
<P align=center><B><U>SIGNATURES</U></B></P>
<P align=justify style="text-indent:5%">Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P style="MARGIN-LEFT: 50%" align=justify><B>ANAVEX LIFE SCIENCES
CORP.</B><BR><I><U>/s/ Christopher Missling</U></I><BR>Name: Christopher
Missling, PhD<BR>Title: Chief Executive Officer <BR>Date: October 6, 2015</P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>exhibit3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>

<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp.: Exhibit 3.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="50%">&nbsp;</td>
    <td width="50%">
    <p align="center"><font size="3">*090303*</font><br>
    *090303</td>
  </tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="5%">
    <img border="0" src="exhibi1.jpg" width="101" height="102"></td>
    <td width="95%">
    <p style="margin-left: 20"><b>BARBARA K. CEGAVSKE<br>
    Secretary of State<br>
    202 North Carson Street<br>
    Carson City, Nevada 89701-4201<br>
    (775) 684-5708<br>
    Website: www.nvsos.gov</b></td>
  </tr>
  <tr>
    <td width="5%">&nbsp;</td>
    <td width="95%">&nbsp;</td>
  </tr>
</table>
<table border="2" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="50%">
  <tr>
    <td width="100%">
    <p align="center"><b><br>
    <font size="3">Certificate of Change Pursuant<br>
    to NRS 78.209</font></b><br>
&nbsp;</td>
  </tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="50%">&nbsp;</td>
    <td width="50%">&nbsp;</td>
  </tr>
  <tr>
    <td width="50%"><font size="1"><b>&nbsp;USE BLACK INK ONLY - DO NOT HIGHLIGHT</b></td>
    <td width="50%">
    <p align="right"><b><font size="1">ABOVE SPACE IS FOR OFFICE USE ONLY</font></font></b></td>
  </tr>
</table>
<p align="center"><u><b><font size="3">Certificate of Change filed Pursuant to
NRS 78.209<br>
For Nevada Profit Corporations</font></b></u></p>
<p align="left"><font size="2">1. Name of corporation:</font></p>
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="100%">Anavex Life Sciences Corp.</td>
  </tr>
</table>
<p>2. The board of directors have adopted a resolution pursuant to NRS 78.209
and have obtained any required approval of the stockholders.</p>
<p>3. The current number of authorized shares and the par value, if any, of each
class or series, if any, of shares before the change:</p>
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="100%">400,000,000 shares of common stock having a par value of
    $0.001 per share</td>
  </tr>
</table>
<p>4. The number of authorized shares and the par value, if any, of each class
or series, if any, of shares after the change:</p>
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="100%">100,000,000 shares of common stock having a par value of
    $0.001 per share</td>
  </tr>
</table>
<p>5. The number of shares of each affected class or series, if any, to be
issued after the change in exchange for each issued share of the same class or
series:</p>
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="100%">1-for-4 reverse stock split on outstanding common stock </td>
  </tr>
</table>
<p>6. The provisions, if any, for the issuance of fractional shares, or for the
payment of money or the issuance of scrip to stockholders otherwise entitled to
a fraction of a share and the percentage of outstanding shares affected thereby:</p>
<table border="1" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="100%">None </td>
  </tr>
</table><BR>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="50%">7. Effective date and time of filing: (optional)</td>
    <td width="5%" style="border-right-style: solid; border-right-width: 1">
    Date:</td>
    <td width="20%" style="border-style: solid; border-width: 1">
    <p align="center">October 6, 2015</td>
    <td width="5%" style="border-left-style: solid; border-left-width: 1; border-right-style: solid; border-right-width: 1">
    <p style="margin-left: 2">Time:</td>
    <td width="20%" style="border-style: solid; border-width: 1">
    <p align="center">4:30 pm EST</td>
  </tr>
  <tr>
    <td width="50%">&nbsp;</td>
    <td width="50%" style="border-right-style: none; border-right-width: medium" colspan="4">
    (must not be later than 90 days after the certificate is filed)</td>
  </tr>
</table>
<p>8. Signature: (required)</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="48%" style="border-bottom-style: solid; border-bottom-width: 1">X&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    <img border="0" src="exhibi2.gif" width="115" height="56"></td>
    <td width="4%" style="border-right-style: solid; border-right-width: 1">&nbsp;</td>
    <td width="48%" style="border-style: solid; border-width: 1">
    <p align="center">President/Chief Executive Officer</td>
  </tr>
  <tr>
    <td width="48%" style="border-top-style: solid; border-top-width: 1"><b>
    Signature of Officer</b></td>
    <td width="4%">&nbsp;</td>
    <td width="48%" style="border-top-style: solid; border-top-width: 1">
    <p align="center">Title</td>
  </tr>
</table>
<p><b>IMPORTANT: </b>Failure to include any of the above information and submit
with the proper fees may cause this filing to be rejected.</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt" bordercolor="#111111" width="100%">
  <tr>
    <td width="50%">This form must be accompanied by appropriate fees.</td>
    <td width="50%">
    <p align="right">Nevada Secretary of State Stock Split<br>
    Revised: 1-5-15</td>
  </tr>
</table><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=center><B><font size="4">Anavex Prepares for Uplisting to NASDAQ, Announces Reverse
Stock Split </font></B></P>
<P align=justify><B>NEW YORK, NY &#150; </B>October 6, 2015 &#150; <U>Anavex Life Sciences
Corp.</U> (&#147;Anavex&#148; or the &#147;Company&#148;) (OTCQX: AVXL), a clinical-stage
biopharmaceutical company developing drug candidates to treat Alzheimer&#146;s
disease, other central nervous system (CNS) diseases, pain, and various types of
cancer, today announced that it is finalizing an application to uplist trading
of its common stock to the NASDAQ Capital Market. To meet the conditions of a
NASDAQ listing, the Company announces a one-for-four (1-for-4) reverse stock
split of its authorized, issued and outstanding common shares. The Company's
common stock will begin trading on a post-split basis at the opening of trading
on October 7, 2015. </P>
<P align=justify>&#147;It is our belief that uplisting to a major exchange will allow
a broader base of worldwide institutions, funds and retail investors to
participate in our future success,&#148; said Christopher U. Missling, PhD, President
and Chief Executive Officer of Anavex. &#147;This reverse stock split will help us
meet the conditions to finalize our application for uplisting to NASDAQ.&#148;</P>
<P align=justify>Following the reverse stock split, every four shares of issued and
outstanding common stock will be converted to one post-reverse split share. All
fractional shares will be rounded up to the nearest whole share. </P>
<P align=justify>The reverse stock split will reduce the issued and outstanding
shares of common stock from 400,000,000 prior to the split to 100,000,000 after
the reverse stock split.</P>
<P align=justify>As of October 7, Anavex common stock will trade under the
ticker symbol AVXLD for a period of 20 business days. After that time or earlier
once NASDAQ approves the uplisting requirements, the &#147;D&#148; will be removed and our
Company's symbol will once again be AVXL. A new CUSIP number will be assigned to
the Company's common stock as a result of the reverse split.</P>
<P align=justify>Shareholders should direct any questions concerning the reverse
split to their bank or broker or the Company's transfer agent, Nevada Agency and
Trust at +1 (775) 322-0626. </P>
<P align=justify><B>About Anavex Life Sciences Corp. </B></P>
<P align=justify>Anavex Life Sciences Corp. (OTCQX: AVXL) is a publicly traded
biopharmaceutical company dedicated to the development of novel drug candidates
to treat Alzheimer&#146;s disease, other central nervous system (CNS) diseases, pain,
and various types of cancer. Anavex&#146;s lead drug candidate, ANAVEX 2-73, is
currently in a Phase 2a clinical trial for Alzheimer&#146;s disease. Initial positive
data was presented at AAIC 2015 and full PART A data is expected by year end.
ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and
muscarinic receptors and successfully completed Phase 1 with a clean data
profile. Preclinical studies demonstrated its potential to halt and/or reverse
the course of Alzheimer&#146;s disease. It has also exhibited anticonvulsant,
anti-amnesic, neuroprotective and anti-depressant properties indicating its
potential to treat additional CNS disorders. Further information is available at
<U>www.anavex.com</U>.</P>
<P align=justify><B>Forward-Looking Statements </B></P>
<P align=justify>Statements in this press release that are not strictly
historical in nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may
differ materially from those projected in any of such statements due to various
factors, including the risks set forth in the Company&#146;s most recent Annual
Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their entirety by this
cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to
revise or update this press release to reflect events or circumstances after the
date hereof. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify><B>For further information: </B></P>
<P align=justify>Anavex Life Sciences Corp. <BR>Research &amp; Business
Development <BR>Toll-free: 1-844-689-3939 <BR>Email: <U>info@anavex.com</U> </P>
<P align=justify>Shareholder &amp; Media Relations <BR>Toll-free: 1-866-505-2895
<BR>Outside North America: +1 (416) 489-0092 <BR>Email: <U>ir@anavex.com</U>
<BR><U>www.anavex.com</U> </P>
<P align=center># # # </P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>exhibi1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibi1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MA[PSI?A>P^R:9!LW8,LKG=),W]YF[GVZ#H !Q7#.<IOFD[LJUC7J0"@ H *
M"@ H KWMC::C:M;7UK#<V[?>CF0.I_ T <A??"?PI=DF&VN+(G_GVN&"CZ(<
MJ/P%;K$54K<VGGK^8K(RV^"FBY^76-4 ]#Y!_P#:5'MW_+'_ ,!06\R>W^#7
MAZ)@9KW4[D?W7E1!^<:*?UI_6*B^&R]$E^@6[G4Z/X/\/:#()=-TF"&<?\MF
<!>7_ +[;+?K6,YRF[R=QI6V-NI * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>exhibi2.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibi2.gif
M1TE&.#EA<P X /<       @(" D)"0H*"@L+"PP,# T-#0X.#@\/#Q 0$!$1
M$1(2$A,3$Q04%!45%186%A<7%Q@8&!D9&1H:&AL;&QP<'!T='1X>'A\?'R @
M("$A(2(B(B,C(R0D)"4E)28F)B<G)R@H*"DI*2HJ*BPL+"TM+2XN+B\O+S P
M,#$Q,3(R,C4U-38V-C<W-S@X.#DY.3HZ.CL[.SP\/#T]/3X^/C\_/T! 0$%!
M04)"0D-#0T5%149&1D='1TE)24I*2DQ,3$]/3U%145)24E-34U145%555596
M5EA86%E965I:6EM;6UQ<7%U=75]?7V%A86)B8F-C8V1D9&5E969F9FAH:&EI
M:6IJ:FMK:VQL;&UM;6YN;F]O;W%Q<7-S<W1T='9V=G=W=WAX>'EY>7IZ>GQ\
M?'Y^?G]_?X" @(*"@H.#@X2$A(6%A8:&AH>'AXB(B(F)B8J*BHN+BXR,C(Z.
MCH^/CY&1D9*2DI.3DY24E)65E9:6EI>7EYB8F)F9F9J:FIN;FYR<G)V=G9Z>
MGJ"@H**BHJ.CHZ2DI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O
MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+Z^OK^_
MO\# P,'!P</#P\3$Q,7%Q<;&QL?'Q\C(R,G)R<K*RLO+R\S,S,W-S<_/S]#0
MT-'1T=+2TM/3T]34U-75U=;6UM?7U]C8V-G9V=K:VMO;V]S<W-W=W=[>WM_?
MW^#@X.'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOKZ^SL[.WM[>[N
M[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ^OO[^_S\_/W]
M_?[^_O___P
M
M                     "'Y!       +     !S #@   C^ +T)'$BPH,!M
MP; 97,BPH<.' Z\%VP:QHL6+&#-JW,BQH\>/($.*'$FRI,F-VIJ=7,DRXZ$?
M+6/*9'A%R\R;-U<8PLDSX[55A?(, @6M(30&LGHJ?:CL3 <(,'S0L*#A%,-7
M$:8MW6KP$ 4<D*0-S!;&!D-(*;BJ]=:MS8-$% NZ4A"WH)X>:[DN<J"*(;
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M- 0,\Q$W1!BA#2</_%(1,SK<T)LU,TQ1%T/!?%!&08Y,$ Q$RF#! !_;[I+
MPQ4Y,\ Q(!53 1HF' B1+2KTT*9 O5@ QL$%S4+"$IL2Q T2.(QKD#:$9'!#
M4@7A4.I#Y#4CP+4?E7* F ]AH\<"7#1&T"LAR% (+]%D<XTSO6QBQ0)>O%O0
M,S+44(K7!W7B @>&L"Q0* S,XI Q/8#"3 #)A/2* @R@X73^0=R,(@,'E6Q;
MD#-LF+  !!5,\, "&4"1BN!?9_% !T6<X8<A;;P  1HY+M1-&'7V&-$C' PQ
MC=!$=Y1-"UR@,D(*=)@2S#/76 .,(CDT8$9^$"U#2RJLX,(,Y$9ID@83.L@P
MQ![*0+3-&@W4.@DIG@ RQ089]+'I,P,0 Q(;)>0731\[2-"  Q \P  ):=A;
M7C%X$%&"!1S4P$4ER'H330' ?)3* @L22#:0@8M7P*(8Q(-/ KU1#03DPB/2
M*($9&"22;#1 3ASI1A5J8 T*AD0;%C!%1P[Q %YX,"3<*($E.)(+"!SBA"+1
M01\V$HT5;&&!,,Q(%,2@D6X\ 0:"P<GA1]X@!(W$(0/]$R)(,-$!'"Z$$@H0
MA1)#XHL%<,PBKGC 3J8(DFUX(#8. 8 8QTC&,IKQC&A,HQK7R,8VNE&- K'&
M#H(0,RZ"Y XZ<*(WMF&%%###CB(I5^<6P@TP9& 7@!3)H2[A$#U0@&>)#$D7
2"-,0!6@BDB.9!0-TT9"    [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
